Lung Pathogens Gain 10,000-Fold Tobramycin Resistance via Plasmid Transfer in 17 Patients
Updated
Updated · Nature.com · Jul 23
Lung Pathogens Gain 10,000-Fold Tobramycin Resistance via Plasmid Transfer in 17 Patients
3 articles · Updated · Nature.com · Jul 23
Summary
Researchers traced sudden extreme tobramycin resistance in 17 chronic lung infections to plasmid-borne genes acquired inside patients’ lungs, not the gradual mutation buildup usually blamed for antibiotic failure.
In 8 key cases, previously sensitive Pseudomonas aeruginosa or Achromobacter lineages stayed clonally related yet picked up new plasmids after treatment began, driving average resistance increases of 9,340-fold that often persisted for years.
Genomic and lab-transfer tests showed the plasmids alone reproduced the phenotype, while transient co-infecting species including Pseudomonas putida, Achromobacter and Stenotrophomonas maltophilia likely carried identical plasmids into the lungs.
The most common element was a previously unrecognized resistance gene, aac(3)-IIId, embedded in the TnCF1 transposon; a single copy raised tobramycin resistance 1,000-fold and TnCF1 appeared in pathogens from 15 countries.
Because the plasmids were highly stable and imposed minimal fitness costs, the study suggests standard susceptibility testing, drug holidays and current infection-control assumptions may miss a fast, durable route to treatment failure.
Could the sudden failure of lung infection treatments be driven by environmental bacteria secretly passing resistance genes inside patients' airways?
What if stopping untreatable respiratory infections requires targeting the lung's hidden bacterial biofilms rather than the pathogens themselves?
10,000-Fold Tobramycin Resistance in Chronic Lung Infections: The Plasmid-Driven Crisis and the Urgent Need for New Diagnostics and Therapies
Overview
A groundbreaking 2026 study revealed that patients with chronic lung infections, especially those with cystic fibrosis, can suddenly develop extreme tobramycin resistance after starting high-dose therapy. This happens when sensitive bacteria in the lungs rapidly acquire resistance plasmids from environmental bacteria through horizontal gene transfer, a process made easier by dense biofilms in the lungs. These plasmids not only protect against antibiotics but also persist even without ongoing treatment, leading to lasting infections, lung damage, and higher rates of lung transplantation. Standard lab tests often miss this resistance, highlighting the urgent need for new diagnostics and therapies targeting plasmid transfer and biofilm formation.